Raludotatug deruxtecan (R-DXd) earned FDA breakthrough designation for CDH6-expressing platinum-resistant ovarian cancers after bevacizumab (Avastin; Genentech) treatment.
Jax DiEugenio
Advertisement
Articles by Jax DiEugenio
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Oral PCSK9 Inhibitor Enlicitide Matches Injectables in Lowering LDL Cholesterol
2
Improving Patient-Centered Cardiovascular Care for Older Adults
3
Introduction of Work Requirements to Medicaid Enrollment Could Destabilize Health: William Schpero, PhD, MPhil, MPH
4
Gefurulimab for MG Exhibits Lasting Efficacy, Safety in Topline PREVAIL Trial Data
5
